Treatment for paediatric respiratory syncytial virus infection
- PMID: 40246355
- DOI: 10.1016/S2352-4642(25)00097-5
Treatment for paediatric respiratory syncytial virus infection
Conflict of interest statement
I declare grants or contracts paid to my institution from AstraZeneca, Enanta, Icosavax, Merck & Co, and Pfizer; consulting fees paid to my institution from Adiago Therapeutics, AstraZeneca, Cidara Therapeutics, Enanta, Gilead, GSK, Icosavax, Merck & Co, Nuance Pharmaceuticals, Pfizer, Sanofi Pasteur, and Shionogi; and fees for being on a data safety and monitoring board from AbbVie, GSK, and Moderna.
Comment on
-
Efficacy and safety of ziresovir in hospitalised infants aged 6 months or younger with respiratory syncytial virus infection in China: findings from a phase 3 randomised trial with 24-month follow-up.Lancet Child Adolesc Health. 2025 May;9(5):325-336. doi: 10.1016/S2352-4642(25)00067-7. Lancet Child Adolesc Health. 2025. PMID: 40246359 Clinical Trial.
Publication types
LinkOut - more resources
Full Text Sources
